SynthesisFrontiers in endocrinology2025
Effects of Xiangshao granules on clinical symptoms and serum hormone levels of menopausal syndrome: a systematic review and meta-analysis of randomized controlled trials.
Synthesis in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effectiveness and safety of commercial Chinese polyherbal preparations combined with menopausal hormone therapy for perimenopausal symptoms: a network meta-analysis of randomized controlled trials.Frontiers in pharmacology · 2026Pooled it
- Clinical evidence on integrated Chinese-Western medicine for perimenopausal syndrome.Integrative medicine research · 2026Article
- Meta-analysis on the efficacy of liver-soothing formulas for perimenopausal anxiety and depression.World journal of psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the efficacy and safety of Xiangshao granules in improving clinical symptoms and regulating serum hormone levels in patients with menopausal syndrome (MPS). Methods: This study was developed according to the PRISMA 2020 guidelines. Eight databases including PubMed, Web of Science, The Cochrane Library, Embase, CNKI, CBM, Wanfang Database, and VIP database were searched for randomized controlled trials (RCTs) of Xiangshao Granules in the treatment of MPS. The search time was from the listing of Xiangshao Granules (2005) to September 1, 2024. Xiangshao granule was used in experimental group. The control group was treated with placebo, other Chinese patent medicine, or conventional western medicine. The treatment period should be at least 4 weeks. RevMan5.4 was used for bias risk assessment and meta-analysis. Results: A total of 13 randomized controlled trials with 1637 participants were included. The meta-analysis showed that there was statistical significance between Xiangshao granules and control group in improving clinical symptoms (P<0.05). Xiangshao granules could improve the total response rate (OR= 2.78, 95%CI[1.65, 4,68], P<0.05) and reduce Kupperman score (MD=-1.23, 95%CI[-2.10,-0.36], P<0.05). In addition, Xiangshao granules also decreased HAMD score (MD= -2.80, 95%CI[-3.54, -2.07], P<0.05) and HAMA score (MD=-2.52, 95%CI[-3.00,-2.04], P<0.05). In terms of serum hormone levels, there was no significant difference in serum FSH levels between Xiangshao granule group and control group(SMD=-0.81, 95%CI[-2.03, 0.41], P= 0.19). However, the regulating effect of Xiangshao granules on serum LH and E2 levels was statistically significant compared with the control group (P<0.05). The results of subgroup analysis showed that Xiangshao granules were better than other Chinese patent medicines in reducing serum LH levels (SMD=-1.20, 95%C[-1.66,-0.73]I, P<0.05). Xiangshao granules were superior to other Chinese patent medicines or placebo in increasing serum E2 levels (SMD=5.28, 95%CI[4.90, 5.66], P<0.05) (SMD=2.00, 95%CI[1.10, 2.90], P<0.05). Furthermore, the combined use of western medicine and Xiangshao granules was better than HRT or SSRIs alone in reducing serum LH level and increasing serum E2 level (P<0.05). In terms of safety, there was no significant difference in the incidence of adverse reactions among all groups (OR= 1.28, 95%CI[0.80, 2.05], P = 0.31). Conclusion: Xiangshao Granules can effectively relieve the clinical symptoms of MPS patients, improve the scores of anxiety and depression and regulate the level of serum estrogen, with good safety, and is an ideal treatment plan. In the future, multi-center and large sample randomized controlled trials can be conducted for more key clinical indicators to comprehensively analyze the clinical efficacy and applicability of Xiangshao granules in the treatment of MPS. Systematic review registration: https://www.crd.york.ac.uk/, identifier CRD42023405228.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.